Benefits and limitations of breastfeeding for mothers with malignant tumors

Cover Page

Cite item

Full Text

Abstract

In the modern world breastfeeding (BF) is considered as a significant factor in reducing the risk of developing malignant tumors of the mammary gland and ovaries. However, the problem of maintenance or refusing BF in malignant neoplasms (malignant neoplasms) still remains open. In recent years, there has been a steady increase in breast cancer (BC), especially in developed countries, with more than 10% of all breast malignancies (BC) diagnosed in women under 40 years of age. The presented article highlights aspects of maintaining lactation in different periods of the relevance of BF in relation to the timing of manifestation of cancer, and also presents data from the multicenter study POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer) on the possibilities of implementing reproductive function and BF in women receiving therapy for hormone-receptor positive (HR+) BC stages I–III. BF with cancer detected in the postpartum period depends on the treatment of the underlying disease. In patients undergoing surgical treatment, BF is not contraindicated, but it is not always technically possible. During chemotherapy, BF is not recommended. When carrying out radiotherapy, it is possible to undergo BF using a healthy mammary gland. There is currently no evidence to suggest that BF woman diagnosed with cancer may have any negative effects. In general, it has been shown that preserving and maintaining lactation in women with a history of cancer is safe for both mother and child.

About the authors

Olga B. Ladodo

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: o_ladodo@oparina4.ru
ORCID iD: 0000-0002-4720-7231

Cand. Sci. (Med.)

Russian Federation, Москва

Mariia V. Iurova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; Sechenov First Moscow State Medical University (Sechenov University)

Email: m_yurova@oparina4.ru
ORCID iD: 0000-0002-0179-7635

Cand. Sci. (Med.), obstetrician-gynecologist, oncologist

Russian Federation, Moscow; Moscow

Svetlana V. Khokhlova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; Russian Medical Academy of Continuous Professional Education

Email: s_hohlova@oparina4.ru
ORCID iD: 0000-0002-4121-7228

D. Sci. (Med.), Department Head, oncologist

Russian Federation, Moscow; Moscow

Valerii V. Rodionov

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: dr.valery.rodionov@gmail.com
ORCID iD: 0000-0003-0096-7126

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Elena L. Sheshko

Ministry of Health of the Russian Federation

Email: sheshkoel@minzdrav.gov.ru
ORCID iD: 0000-0002-8105-3109

Cand. Sci. (Med.), Assoc. Prof.

Russian Federation, Moscow

Viktor V. Zubkov

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; Sechenov First Moscow State Medical University (Sechenov University)

Email: zubkov_v_v@staff.sechenov.ru
ORCID iD: 0000-0002-9697-9596

Sci. (Med.), neonatologist

Russian Federation, Moscow; Moscow

Mziya I. Makieva

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: m_makieva@oparina4.ru
ORCID iD: 0000-0002-2632-4666

Cand. Sci. (Med.), Department Head, neonatologist

Russian Federation, Moscow

Dar’ia A. Chutkova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Author for correspondence.
Email: huhreva@gmail.com
ORCID iD: 0000-0002-0356-1220

Leading Specialist

Russian Federation, Moscow

Elena S. Akhapkina

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

Email: elena.akhapkins@gmail.com
ORCID iD: 0000-0002-5874-0082

Employee

Russian Federation, Moscow

Dmitriy N. Degtyarev

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; Sechenov First Moscow State Medical University (Sechenov University)

Email: d_degtiarev@oparina4.ru
ORCID iD: 0000-0001-8975-2425

Sci. (Med.), Prof., neonatologist

Russian Federation, Moscow; Moscow

References

  1. Ellington TD, Miller JW, Henley SJ, et al. Trends in breast cancer incidence, by race, ethnicity, and age among women aged ≥20 Years – United States, 1999-2018. MMWR Morb Mortal Wkly Rep. 2022;71(2):43-7. doi: 10.15585/mmwr.mm7102a2
  2. Di Mattei VE, Perego G, Taranto P, et al. Psychological issues in breast cancer survivors confronted with motherhood: Literature review and a call to action. Front Psychol. 2023;14:1133204. doi: 10.3389/fpsyg.2023.1133204
  3. Lambertini M, Di Maio M, Poggio F, et al. Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients. Reprod Biomed Online. 2019;38(5):835-44. doi: 10.1016/j.rbmo.2018.11.031
  4. Galati F, Magri V, Arias-Cadena PA, et al. Pregnancy-associated breast cancer: A diagnostic and therapeutic challenge. Diagnostics (Basel). 2023;13(4):604. doi: 10.3390/diagnostics13040604
  5. Shanmugam S, Balakrishnan S. Association of breast feeding in ovarian malignancy: Is breastfeeding a boon? A single institutional experience. Int J Reprod Contracept Obstet Gynecol. 2023;12(6):1666-9.
  6. Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am. 2012;26(1):1-12. doi: 10.1016/j.hoc.2011.10.009
  7. Holman DA. Fertility preservation in gynecologic cancer. Semin Oncol Nurs. 2019;35(2):202-10. doi: 10.1016/j.soncn.2019.02.007
  8. Юпатов Е.Ю., Курманбаев Т.Е., Шмидт А.А., и др. Криоконсервация репродуктивной ткани – возможность сохранения фертильности (обзор литературы). Проблемы репродукции. 2020;26(5):99-106 [Yupatov EYu, Kurmanbaev TE, Shmidt AA, et al. Cryopreservation of reproductive tissue – the possibility of preserving fertility (a review). Russian Journal of Human Reproduction. 2020;26(5):99-106 (in Russian)]. doi: 10.17116/repro20202605199
  9. Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101(4):1364-71. doi: 10.1210/jc.2015-3878
  10. Lakhoo K, Davies J, Chakraborty S, et al. Development of a new reproductive tissue cryopreservation clinical service for children: The Oxford programme. Pediatr Surg Int. 2019;35(11):1271-8. doi: 10.1007/s00383-019-04503-3
  11. Jordan SJ, Cushing-Haugen KL, Wicklund KG, et al. Breast feeding and risk of epithelial ovarian cancer. Cancer Causes Control. 2012;23(6):919-27. doi: 10.1007/s10552-012-9963-4
  12. Babic A, Sasamoto N, Rosner BA, et al. Association between breastfeeding and ovarian cancer risk. JAMA Oncol. 2020;6(6):e200421. doi: 10.1001/jamaoncol.2020.0421
  13. Bhurosy T, Niu Z, Heckman CJ. Breastfeeding is possible: A systematic review on the feasibility and challenges of breastfeeding among breast cancer survivors of reproductive age. Ann Surg Oncol. 2021;28(7):3723-35. doi: 10.1245/s10434-020-09094-1
  14. Dagla M, Mrvoljak-Theodoropoulou I, Karagianni D, et al. Women’s mental health as a factor associated with exclusive breastfeeding and breastfeeding duration: Data from a Longitudinal Study in Greece. Children (Basel). 2021;8(2):150. doi: 10.3390/children8020150
  15. Johnson HM, Mitchell KB; Academy of Breastfeeding Medicine. ABM Clinical Protocol #34: Breast cancer and breastfeeding. Breastfeed Med. 2020;15(7):429-34. doi: 10.1089/bfm.2020.29157.hmj
  16. Schnitt SJ, Connolly JL, Harris JR, Cohen RB. Radiation-induced changes in the breast. Hum Pathol. 1984;15(6):545-50. doi: 10.1016/s0046-8177(84)80008-8
  17. Leal SC, Stuart SR, Carvalho Hde A. Breast irradiation and lactation: A review. Expert Rev Anticancer Ther. 2013;13(2):159-64. doi: 10.1586/era.12.178
  18. Duffy C, Cyr M. Phytoestrogens: Potential benefits and implications for breast cancer survivors. J Womens Health (Larchmt). 2003;12(7):617-31. doi: 10.1089/154099903322404276
  19. Lambertini M, Blondeaux E, Bruzzone M, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2021;39(29):3293-305. doi: 10.1200/JCO.21.00535
  20. Partridge A, Pagani O, Niman S, et al. abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13). Cancer Research. 2023;83(5 Suppl.): GS4-09-GS4-09. doi: 10.1158/1538-7445.SABCS22-GS4-09
  21. Ogg S, Klosky JL, Chemaitilly W, et al. Breastfeeding practices among childhood cancer survivors. J Cancer Surviv. 2020;14(4):586-99. doi: 10.1007/s11764-020-00882-y
  22. Haliloglu N, Ustuner E, Ozkavukcu E. Breast ultrasound during lactation: Benign and malignant lesions. Breast Care (Basel). 2019;14(1):30-4. doi: 10.1159/000491781
  23. Sabate JM, Clotet M, Torrubia S, et al. Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics. 2007;27(Suppl. 1):S101-24. doi: 10.1148/rg.27si075505
  24. di Florio-Alexander RM, Slanetz PJ, Moy L, et al.; Expert Panel on Breast Imaging. ACR Appropriateness Criteria® breast imaging of pregnant and lactating women. J Am Coll Radiol. 2018;15(11S):S263-75. doi: 10.1016/j.jacr.2018.09.013
  25. Chung M, Ruiz-Cordero R, Lee AY, et al. MRI evaluation of the lactating breast. Curr Radiol Rep. 2022;10(5):57-67. doi: 10.1007/s40134-022-00395-9
  26. Lo AC, Ronckers C, Aznar MC, et al. Breast hypoplasia and decreased lactation from radiation therapy in survivors of pediatric malignancy: A PENTEC comprehensive review. Int J Radiat Oncol Biol Phys. 2021:S0360-3016(21)02725-5. doi: 10.1016/j.ijrobp.2021.08.032
  27. Wheeler G, Grassberger C, Samers J, et al. Central endocrine complications among childhood cancer survivors treated with radiation therapy: A PENTEC comprehensive review. Int J Radiat Oncol Biol Phys. 2023:S0360-3016(23)00416-9. doi: 10.1016/j.ijrobp.2023.04.024
  28. Radiotherapy. In: Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development, 2006. Available at: https://pubmed.ncbi.nlm.nih.gov/30000783/ Accessed: 30.07.2023.
  29. Pistilli B, Bellettini G, Giovannetti E, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013;39(3):207-11. doi: 10.1016/j.ctrv.2012.10.002
  30. Begg EJ, Duffull SB, Hackett LP, Ilett KF. Studying drugs in human milk: Time to unify the approach. J Hum Lact. 2002;18(4):323-32. doi: 10.1177/089033402237904
  31. Shachar SS, Gallagher K, McGuire K, et al. Multidisciplinary management of breast cancer during pregnancy. Oncologist. 2017;22(3):324-34. doi: 10.1634/theoncologist.2016-0208
  32. Sella T, Sorouri K, Rosenberg Sh, et al. abstract P5-08-06: Breastfeeding in survivors of early breast cancer. Cancer Research. 2023;83: P5-08. doi: 10.1158/1538-7445.SABCS22-P5-08-06
  33. Linkeviciute A, Notarangelo M, Buonomo B, et al. Breastfeeding after breast cancer: Feasibility, Safety, and ethical perspectives. J Hum Lact. 2020;36(1):40-3. doi: 10.1177/0890334419887723
  34. Vandenbroucke T, Verheecke M, van Gerwen M, et al. Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy. Eur J Cancer. 2020;138:57-67. doi: 10.1016/j.ejca.2020.07.004
  35. Schwarz EB, Hess R, Trussell J. Contraception for cancer survivors. J Gen Intern Med. 2009;24(Suppl. 2):S401-6. doi: 10.1007/s11606-009-1023-8
  36. Юрова М.В., Межевитинова Е.А., Якушевская О.В., и др. Влияние гормональной контрацепции на риск развития рака молочной железы. Современная Онкология. 2023;25(2):199-207 [Iurova MV, Mezhevitinova EA, Yakushevskaya OV, et al. The effect of hormonal contraception on the risk of breast cancer: A review. Journal of Modern Oncology. 2023;25(2):199-207 (in Russian)]. doi: 10.26442/18151434.2023.2.202287
  37. FSRH Guideline Contraception After Pregnancy. Faculty of Sexual & Reproductive Healthcare, 2020. Available at: https://www.fsrh.org/standards-and-guidance/documents/contraception-after-pregnancy-guideline-january-2017/ Accessed: 30.07.2023.
  38. Чернуха Г.Е., Пронина В.А. Низкодозированная внутриматочная контрацепция – инновационный подход к профилактике нежелательной беременности. Медицинский совет. 2022;16(5):40-5 [Chernukha GE, Pronina VA. Low-dose intrauterine contraception is an innovative approach to the prevention of unwanted pregnancy. Meditsinskiy Sovet. 2022;16(5):40-5 (in Russian)]. doi: 10.21518/2079-701X-2022-16-5-40-45

Copyright (c) 2024 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies